Safety evaluation of salmon extract containing anserine

Safety evaluation of salmon extract containing anserine - Safety evaluation of salmon extract containing anserine

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000031251

Enrollment

Registered

2018-02-12

Start date

2018-02-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Ingestion of 3.3 g / day of salmon extract (1 g as anserine) for 30 days

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Healthy middle-to-elderly volunteer. 2) Subjects who can make self-judgment and are voluntarily giving written informed consent.

Exclusion criteria

Exclusion criteria: 1) Subjects who have total serum cholesterol over 260 mg/dL. 2) Subjects who have ALT, AST and gamma-GTP more than twice the standard value.

Design outcomes

Primary

Measure	Time frame
Safety : Adverse effects	—

Secondary

Measure	Time frame
hematological test (WBC, RBC, Hb, Ht, and Plt), blood biochemical test (AST, ALT, gamma-GTP, ALP, ALB, serum amylase, TC, LDL-C, HDL-C, TG, fasting blood glucose, HbA1c, UA, CRE, BUN and CRP) before ingestion and after 30 days	—

Countries

Japan

Contacts

Public ContactKenichiro Sato

Tokaibussan Co., Ltd Sales department

sato@tokaibsn.co.jp03-3864-6861

Outcome results